# Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT01006265** · PHASE2 · COMPLETED · sponsor: **Actelion** · enrollment: 464 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** ACT-128800 Dose 1
- **DRUG:** Placebo
- **DRUG:** ACT-128800 Dose 2
- **DRUG:** ACT-128800 Dose 3

## Key facts

- **NCT ID:** NCT01006265
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-01
- **Primary completion:** 2011-06-01
- **Final completion:** 2011-07-01
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006265, "Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01006265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*